Weekly paclitaxel/5-fluorouracil followed by platinum retreatment for patients with recurrent ovarian cancer: A single institution experience

European Journal of Gynaecological Oncology

Volumn 29, Issue 6, 2008, Pages 573-577

  Watari, H ^a   Hosaka, M ^a   Mitamura, T ^a   Moriwaki, M ^a   Ohba, Y ^a   Todo, Y ^a   Takeda, M ^a   Ebina, Y ^a   Sakuragi, N ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

5 fluorouracil; Ovarian cancer; Paclitaxel; Platinum free interval; Recurrent disease

Indexed keywords

CA 125 ANTIGEN; CARBOPLATIN; CISPLATIN; DOCETAXEL; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; PACLITAXEL; PLATINUM; SEROTONIN ANTAGONIST;

ADULT; AGED; ANEMIA; ARTHRALGIA; ARTICLE; BILIRUBIN BLOOD LEVEL; BLOOD TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; HUMAN; LEUKOPENIA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAIL DISEASE; NAUSEA AND VOMITING; OVARY CANCER; PERIPHERAL NEUROPATHY; PROGNOSIS; RECURRENT CANCER; RETREATMENT; SIDE EFFECT; THROMBOCYTOPENIA;

ADENOCARCINOMA, PAPILLARY; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CYSTADENOCARCINOMA, SEROUS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PACLITAXEL;

EID: 56749153316     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Amstrong D.K.: "Relapesed ovarian cancer: challenges and management strategies for a chronic disease". Oncologist, 2002, 7 (suppl. 5), 20.
2. Jemal A., Thomas A., Murray T., Thun M.: "Cancer statistics, 2002". CA Cancer J. Clin., 2002, 52, 23.
3. Markman M., Hall J., Spitz D., Weiner S., Carson L., Le L.V. et al.: "Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer". J. Clin. Oncol., 2002, 20, 2365.
4. 2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study". Gynecol. Oncol., 2006, 101, 436.
5. Blackledge G., Lawton F., Redman C., Kelly K.: "Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials". Br. J. Cancer 1989, 59, 650.
6. Gore M.E., Fryatt I., Wiltshaw E., Dawson T.: "Treatment of relapsed carvinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds". Gynecol. Oncol., 1990, 36, 207.
7. Markman M., Rothman R., Hakes T., Reichman B., Hoskins W., Robin S. et al.: "Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin". J. Clin. Oncol., 1991, 9, 389.
8. Parmar M.K., Ledermann J.A., Colombo N., du Bois A., Delalovo J.F., Kristensen G.B. et al.: "ICON and AGO Collaborators. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer. The ICON4/SGO-OVAR-2.2 trial". Lancet, 2003, 361, 2099.
9. Pfisterer J., Plante M., Vergote I., du Bois A., Hirte H., Lacave A.J. et al.: "AGO-OVAR: NCIC CTG: EORTC GOG. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GOG". J. Clin. Oncol., 2006, 24, 4699.
10. Murad A.M., Petroianu A., Guimaraes R.C., Aragao B.C., Cabral L.O., Scalabrini-Neto A.O.: "Phase II trial of the combination of paclitaxel and 5-fluorouracil in the treatment of advanced gastric cancer: a novel, safe, and effective regimen". Am. J. Clin. Oncol., 1999, 22, 580.
11. Loesch D.M., Asmar L., Canfield V.A., Parker G.A., Hynes H.E., Ellis P.G. et al.: "A phase II trial of weekly paclitaxel, 5-fluorouracil, and leucovorin as first-line treatment for metastatic breast cancer". Breast Cancer Res. Treat., 2003, 77, 115.
12. Sugiyama T., Yakushiji M., Nishida T., Ushijima K., Okura N., Kigawa J. et al.: "Irinotecan (CPT-11) combined with cisplatin in patients with refractory or recurrent ovarian cancer". Cancer Lett., 1998, 128, 211.
13. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L. et al.: "New guideline to evaluate the response to treatment in solid tumors". J. Natl. Cancer Inst., 2000, 92, 205.
14. Rustin G.J.S., Nelstrop A.E., McClean P., Brady M.F., McGuire W.P., Hoskins W.J. et al.: "Defining response of ovarian carcinoma to initial chemotherapy according to serum CA-125". J. Clin. Oncol., 1996, 14, 1545.
15. Kano Y., Akutsu M., Tsunoda S., Ando J., Matsui J., Suzuki K. et al.: "Schedule-dependent interaction between paclitaxel and 5-fluorouracil in human carcinoma cell lines in vitro". Br. J. Cancer, 1996, 74, 704.
16. Cascinu S., Ficarelli R., Safi M.A.A., Graziano F., Catalano G., Cellerino R.: "A phase I study of paclitaxel and 5-fluorouracil in advanced gastric cancer". Eur. J. Cancer, 1999, 33, 1699.
17. Nistico C., Bria E., Agostara B., Barni S., Colella E., Frontini L. et al.: "Weekly paclitaxel, 5-fluorouracil and folinic acid with granulocyte colonu-stimulating factor support in metastatic breast cancer patients: a phase II study". Anticancer Drugs, 2006, 17, 345.
18. Cesano A., Lane S.R., Poulin R., Ross G., Fields S.Z.: "Stabilization of disease as a useful predictor of survival following second-line chemotherapy in small cell lung cancer and ovarian cancer patients". Int. J. Oncol., 1999, 15, 1233.
19. Kavanagh J., Tresukosol D., Edwards C., Freedman R., Gonzalez de Leon C., Fishman A. et al.: "Carboplatin reinduction after taxane in patients with platinum-refractory epithelial ovarian cancer". J. Clin. Oncol., 1995, 13, 1584.